Abstract
The damage to humanity and global healthcare done by the COVID-19 pandemic is hard to overestimate. According to the World Health Organization (WHO), there were more than 500 million confirmed cases of SARS-CoV-2 infection, more than 6 million of which were fatal. The high incidence of arterial thrombosis and venous thromboembolic complications despite the ongoing antithrombotic therapy, often leading to death in patients with new coronavirus infection SARS-CoV-2, indicates the need for profound study of the pathogenetic aspects of procoagulant status and a more rational personalized approach in prophylactic measures in this category of patients. Special interest is the development of thrombotic complications in COVID-19 convalescents. This article presents a clinical case of a 43-year-old man with no cardiovascular history who suffered viral myocarditis with thrombus formation in the heart cavities, thrombosis of deep veins of the lower extremities and consequent pulmonary thromboembolism, all of which developed within a month after coronavirus infection. In the article authors discuss the leading pathophysiological mechanisms that potentially could propagate the development of thrombosis and thromboembolic complications in patients with COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
